Diabetic macular edema shows a positive response to Aflibercept after previous unresponsive intravitreal Anti-VEGF and steroid therapy
Purpose: To evaluate the efficacy of intravitreal aflibercept in diabetic macular edema unresponsive to prior intravitreal anti VEGF and steroid therapy.
Materials and Methods: 10 eyes were prospectively investigated. Each eye was treated with intravitreal aflibercept in case of central macular edema unresponsive to prior anti VEGF therapy and intravitreal steroid. Patient were evaluated preoperatively with BCVA, OCT and fundus evaluation and IOP and followed up at 15 days, 6 weeks.
Results: Mean BCVA at presentation was 0.85 log MAR, and that improved to at 15 days and 45 days of intravitreal aflibercept, 0.65 log MAR and 0.52 log MAR. Mean central macular edema at presentation was 662.5 µm (380-905µm), after 15 days was 403µm (185-705µm) and after 45 days was 261.25µm (120-507 µm).
Conclusion: Intravitreal aflibercept can be an option to treat unresponsive diabetic central macular edema.
Keywords: VEGF, Intravitreal Aflibercept.
Materials and Methods: 10 eyes were prospectively investigated. Each eye was treated with intravitreal aflibercept in case of central macular edema unresponsive to prior anti VEGF therapy and intravitreal steroid. Patient were evaluated preoperatively with BCVA, OCT and fundus evaluation and IOP and followed up at 15 days, 6 weeks.
Results: Mean BCVA at presentation was 0.85 log MAR, and that improved to at 15 days and 45 days of intravitreal aflibercept, 0.65 log MAR and 0.52 log MAR. Mean central macular edema at presentation was 662.5 µm (380-905µm), after 15 days was 403µm (185-705µm) and after 45 days was 261.25µm (120-507 µm).
Conclusion: Intravitreal aflibercept can be an option to treat unresponsive diabetic central macular edema.
Keywords: VEGF, Intravitreal Aflibercept.